CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Study Number

2024021

Phase

I/II

Age Group

Adult

Pediatric

Principal Investigator

Ajay Gupta

Purpose

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors

Check your eligibility for this trial

Check now

Full Title

A Phase 1/2 Dose escalation and dose expansion study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

ClinicalTrials.Gov ID

NCT03425279

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.